Breaking News

Tweet TWEET

Financial Results Release, Management Changes, and Newly Issued Permits - Research Report on Valeant, Teva, Endo, Array, and

  Financial Results Release, Management Changes, and Newly Issued Permits -
         Research Report on Valeant, Teva, Endo, Array, and Sequenom

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, August 12, 2013

NEW YORK, August 12, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Valeant
Pharmaceuticals International, Inc. (NYSE: VRX), Teva Pharmaceutical
Industries Ltd (NYSE: TEVA), Endo Health Solutions Inc. (NASDAQ: ENDP), Array
BioPharma Inc. (NASDAQ: ARRY), and Sequenom, Inc. (NASDAQ: SQNM). Today's
readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

Valeant Pharmaceuticals International, Inc. Research Report

On August 7, 2013, Valeant Pharmaceuticals International, Inc. (Valeant)
reported its Q2 2013 financial results. Total revenues for Q2 2013 were $1.1
billion, up 33.6% YoY. The Company's Q2 2013 net income was $10.9 million, or
$0.03 per diluted share, compared with a net loss of $21.6 million, or $0.07
per diluted share, in Q2 2012. J. Michael Pearson, Chairman and CEO of Valeant
said, "We are particularly pleased with the performance of our Emerging
Markets segment, which delivered organic growth of 14%." The Full Research
Report on Valeant Pharmaceuticals International, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/9fdd_VRX]

--

Teva Pharmaceutical Industries Ltd Research Report

On August 5, 2013, Teva Pharmaceutical Industries Ltd (Teva) announced the
appointments of Ika Abravanel as Executive Vice President of Teva Corporate in
Israel and Global Community Alliances, effective September 1, 2013, and of
Mark Sabag as Group Executive Vice President of Human Resources at Teva,
effective August 11, 2013. According to the Company, Abravanel and Sabag will
serve on the Company's Executive Committee and will report to Dr. Jeremy
Levin, President and CEO of Teva. The Full Research Report on Teva
Pharmaceutical Industries Ltd - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/e3a3_TEVA]

--

Endo Health Solutions Inc. Research Report

On August 6, 2013, Endo Health Solutions Inc. (Endo) reported its Q2 2013
financial results. In Q2 2013, the Company reported total revenues of $766.5
million, down 2.4% YoY. Q2 2013 adjusted net income came in at $166.3 million,
or $1.42 per diluted share, compared with $154.2 million, or $1.27 per diluted
share in Q2 2012. Rajiv De Silva, President and CEO of Endo said, "Our expense
reduction efforts are on track to meet our objectives, we have made progress
in the exploration of strategic alternatives for HealthTronics and our branded
pharmaceutical discovery platform, and we have positive organic growth
momentum within each of our core businesses." The Full Research Report on Endo
Health Solutions Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/059c_ENDP]

--

Array BioPharma Inc. Research Report

On August 7, 2013, Array BioPharma Inc. (Array) reported financial results for
Q4 FY 2013 and full-year FY 2013 (period ended June 30, 2013). Revenue for Q4
FY 2013 was $25.4 million, up 23% YoY. Net loss was $17.6 million, or $0.15
per share, compared with net loss of $8 million, or $0.09 per share, in Q4 FY
2012. For full-year FY 2013, the Company reported revenue of $69.6 million,
down 18.3% YoY. Net loss for full-year FY 2013 was $61.9 million, or $0.57 per
share, compared with net loss of $23.6 million, or $0.33 per share, in
full-year FY 2012. "Array has made important progress over the past year
generating data with ARRY-520 and ARRY-614 to inform pivotal trial decisions
by the end of calendar 2013," said Ron Squarer, CEO of Array. "In July, we
shared positive results from our Phase 2 study of ARRY-502 which demonstrated
its potential to become the first new oral medication for asthma since
Singular was approved 15 years ago." The Full Research Report on Array
BioPharma Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/e048_ARRY]

--

Sequenom, Inc. Research Report

On August 5, 2013, Sequenom, Inc. (Sequenom) announced that the New York
Department of Health's Wadsworth Center Clinical Laboratory Evaluation Program
(CLEP) has issued a clinical laboratory permit, which allows the Sequenom
Center for Molecular Medicine's (Sequenom CMM) San Diego facility to provide
the MaterniT21 PLUS test to healthcare professionals in New York. According to
the Company, this permit is in effect since August 1, 2013. Further, the
Company also announced that Sequenom CMM's CLIA laboratory in North Carolina
has received accreditation by the College of American Pathologists (CAP),
which establishes that the facility has met all the applicable standards
required to provide quality laboratory services. "The New York licensure and
approval process is a very detailed and complex evaluation by a regulatory
body to ensure the accuracy and reliability of laboratory testing that is
provided throughout New York State, and we believe the successful CLEP permit,
in addition to the recent CAP accreditation in North Carolina, further
validate the clinical, technical, and scientific merits of our
industry-leading noninvasive prenatal technology," said Allan Bombard, M.D.,
Chief Medical Officer of Sequenom. The Full Research Report on Sequenom, Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/d291_SQNM]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Analysts' Corner
 
Press spacebar to pause and continue. Press esc to stop.